Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Dempster

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Jornal Brasileiro De Nefrologia|December 10, 2015
New insights on diabetes and bone metabolismCarolina A Moreira, Fellype C Barreto, David W Dempster
The Prostate|May 7, 2004
Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cellsThambi Dorai, Janice P Dutcher, David W Dempster, et al.
Clinical Therapeutics|March 24, 2012
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical dataDavid W Dempster, Cheryl L Lambing, Paul J Kostenuik, et al.
Bone|October 24, 2006
Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activityAkiko Iida-Klein, Shi Shou Lu, Felicia Cosman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2007
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human iliumRobert Lindsay, Hua Zhou, Felicia Cosman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 27, 2016
Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on AlendronateDavid W Dempster, Felicia Cosman, Hua Zhou, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 1, 2003
Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivoAkiko Iida-Klein, Shi Shou Lu, Ken Yokoyama, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 6, 2022
Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 yearsDelphine Farlay, Sébastien Rizzo, David W Dempster, et al.
Endocrinology|June 16, 2007
The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J miceSara Johnston, Sharon Andrews, Victor Shen, et al.
JBMR Plus|June 30, 2021
Ten-Year Simulation of the Effects of Denosumab on Bone Remodeling in Human BiopsiesDuncan C Tourolle, David W Dempster, Charles Ledoux, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Jornal Brasileiro De Nefrologia|December 10, 2015
New insights on diabetes and bone metabolismCarolina A Moreira, Fellype C Barreto, David W Dempster
The Prostate|May 7, 2004
Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cellsThambi Dorai, Janice P Dutcher, David W Dempster, et al.
Clinical Therapeutics|March 24, 2012
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical dataDavid W Dempster, Cheryl L Lambing, Paul J Kostenuik, et al.
Bone|October 24, 2006
Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activityAkiko Iida-Klein, Shi Shou Lu, Felicia Cosman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2007
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human iliumRobert Lindsay, Hua Zhou, Felicia Cosman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 27, 2016
Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on AlendronateDavid W Dempster, Felicia Cosman, Hua Zhou, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 1, 2003
Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivoAkiko Iida-Klein, Shi Shou Lu, Ken Yokoyama, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 6, 2022
Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 yearsDelphine Farlay, Sébastien Rizzo, David W Dempster, et al.
Endocrinology|June 16, 2007
The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J miceSara Johnston, Sharon Andrews, Victor Shen, et al.
JBMR Plus|June 30, 2021
Ten-Year Simulation of the Effects of Denosumab on Bone Remodeling in Human BiopsiesDuncan C Tourolle, David W Dempster, Charles Ledoux, et al.
Pageof 11